CHICAGO -- A bumetanide nasal spray in development for heart failure was well-tolerated and showed reliable rates of absorption compared with oral and intravenous delivery in a phase I trial of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback